• Despite major advances in infection control, infectious disease continues to be a huge burden in terms of disability, human performance, and costs to healthcare systems.

Faced with the rise of bacterial and fungal hospital infections and the ubiquitous problems of resistance, pharmaceutical manufacturers are adjusting their strategic focus to familiar mechanisms of action.

At the same time, the market is increasingly interested in targeted therapies.

Marketers bringing new anti-infective products to market face a unique challenge in that their new ideal product may be ‘held in reserve’ due to concerns about fostering resistance to the latest ‘biggest gun.’

Our senior consultants highlight some of the market research implications in an article published in the Fall 2010 issue of QRCA Views, such as a need to focus on the science, consider a range of attributes, and to choose the right respondents.

Observant LLC conducts high-impact studies for clients across the product lifecycle in infectious disease.

Please click on the fields below for recent research examples, and here for a recent case study leveraging a novel technique to assess attribute importance for a new antibiotic.

For more information about Observant LLC’s expertise in this area, or to discuss potential infectious disease research engagements, please contact: ID@observant.biz